{"title":"Novel Treatment Options for Knee Cartilage Defects in 2023.","authors":"Claudia Ghisa, Kenneth R Zaslav","doi":"10.1097/JSA.0000000000000398","DOIUrl":null,"url":null,"abstract":"<p><p>Articular cartilage lesions are a common injury that have become increasingly treatable with joint preservation procedures. Well-documented allograft and cellular treatments for these lesions are detailed elsewhere in this volume. This article discusses three new unique options for addressing these defects taking three different paths to address these complex injuries. Agili-C is an existing FDA- and EMEA-approved option using an acellular aragonite-based scaffold to treat both chondral and osteochondral lesions, with or without concurrent arthritis. Cartistem is a stem-cell-based product composed of culture-expanded allogeneic human umbilical cord blood-derived mesenchymal stem cells and hyaluronic acid hydrogel, which is in its final clinical trial stages in the United States, but already has regulatory approval in Korea. IMPACT and RECLAIM studies have shown the safety and efficacy of a new one-stage procedure utilizing autologous chondrons combined with allogeneic mesenchymal stem cells (MSCs) that can provide another effective single-stage treatment option.</p>","PeriodicalId":49481,"journal":{"name":"Sports Medicine and Arthroscopy Review","volume":"32 2","pages":"113-118"},"PeriodicalIF":2.5000,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Sports Medicine and Arthroscopy Review","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/JSA.0000000000000398","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/3 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"SPORT SCIENCES","Score":null,"Total":0}
引用次数: 0
Abstract
Articular cartilage lesions are a common injury that have become increasingly treatable with joint preservation procedures. Well-documented allograft and cellular treatments for these lesions are detailed elsewhere in this volume. This article discusses three new unique options for addressing these defects taking three different paths to address these complex injuries. Agili-C is an existing FDA- and EMEA-approved option using an acellular aragonite-based scaffold to treat both chondral and osteochondral lesions, with or without concurrent arthritis. Cartistem is a stem-cell-based product composed of culture-expanded allogeneic human umbilical cord blood-derived mesenchymal stem cells and hyaluronic acid hydrogel, which is in its final clinical trial stages in the United States, but already has regulatory approval in Korea. IMPACT and RECLAIM studies have shown the safety and efficacy of a new one-stage procedure utilizing autologous chondrons combined with allogeneic mesenchymal stem cells (MSCs) that can provide another effective single-stage treatment option.
期刊介绍：
Sports Medicine and Arthroscopy Review helps physicians digest the large volume of clinical literature in sports medicine and arthroscopy, identify the most important new developments, and apply new information effectively in clinical practice. Each issue is guest-edited by an acknowledged expert and focuses on a single topic or controversy. The Guest Editor invites the leading specialists on the topic to write review articles that highlight the most important advances. This unique format makes the journal more in-depth, authoritative, and practical than most publications in this field. The journal also includes dozens of full-color and black-and-white arthroscopic images and illustrations.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
